Several trials studying combination of PARP inhibitor plus ICIs are ongoing, for both pre-treated ED-SCLC (phase 2 NCT04701307, phase 1/2 NCT04728230), and for the maintenance/consolidation therapy following first-line treatment (phase 2 NCT04782089, phase 2 NCT04334941, phase 1b/2 NCT03830918). This evidence concerns the gene PARP1 and small cell lung carcinoma.